SCHEMBL15977825

SCHEMBL15977825

c1ccc(-c2ccc(-c3ccc4c(-c5ccc(-c6ccc7ccccc7c6)cc5)c5ccccc5c(-c5ccc(-c6ccc7ccccc7c6)cc5)c4c3)nc2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 1/20 0.43
KLF5 Q13887 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SIRT2 Q8IXJ6 4/20 0.42
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
DCTPP1 Q9H773 1/20 0.40
DHODH Q02127 1/20 0.39
PRMT5 O14744 2/20 0.39
WDR77 Q9BQA1 1/20 0.39
CYP17A1 P05093 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15977693 0.95 SMN1; SMN2 (0.45) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL15977527 0.94 KDM4E (0.42) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL15977528 0.94 KDM4E (0.42) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL15977508 0.94 KDM4E (0.44) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL15181214 0.93 KDM4E (0.43) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL15977467 0.91 KDM4E (0.44) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL15977931 0.91 SMN1; SMN2 (0.48) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL13658732 0.90 KDM4E (0.45) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL10030057 0.90 SMN1; SMN2 (0.49) ABL1SMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL12322255 0.89 SIRT2 (0.42) ABL1SMN1; SMN2KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO.,LTD. (JP) 2022-12-29 US disclosed
US-9559311-B2 Anthracene derivative, organic-electroluminescence-device material, organic electroluminescence device, and electronic equipment IDEMITSU KOSAN CO., LTD. (JP) 2017-01-31 US disclosed
US-9559311-B2 Anthracene derivative, organic-electroluminescence-device material, organic electroluminescence device, and electronic equipment IDEMITSU KOSAN CO., LTD. (JP) 2017-01-31 US disclosed
US-20140239273-A1 ANTHRACENE DERIVATIVE, ORGANIC-ELECTROLUMINESCENCE-DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-08-28 US disclosed
US-20140239273-A1 ANTHRACENE DERIVATIVE, ORGANIC-ELECTROLUMINESCENCE-DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS PIEZO1, TMEM109, SLC39A14 ABL1 2941/4885SMN1; SMN2 3245/4885KDM4E 3416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.